For patients ≥1 year of age with
Short Bowel Syndrome (SBS) who are
dependent on parenteral support (PS)1*
Put the Missing Piece in Place
Color of bag may vary
based on patient.
Let’s Get Started
Select the option that fits you best and we’ll guide you to relevant resources.
Thank You
Explore the GATTEX materials below or get in touch with a rep.
Safety in Adults and Pediatrics Explore the GATTEX safety profile in adults and pediatric patients.
Start Form If GATTEX is the right choice for your patients, begin today using the online or print start form, designed to help clinicians start patients on treatment.
Real-World Experience Explore real-world patient experiences on GATTEX.
Request a Rep Sign up for emails or schedule a rep visit to learn more about GATTEX.
Thank You
These links can provide helpful tools for your patients and your practice.
Dosing Guide Review common diagnosis codes and the recommended dosage of GATTEX for all patients.
Weaning Process Learn more about weaning SBS-IF patients off parenteral support.
Real-World Experience Explore real-world patient experiences on GATTEX.
Request a Rep Sign up for emails or schedule a rep visit to learn more about GATTEX.
Thank You
These resources provide insight into GATTEX and weaning off PS.
Dosing Guide Review common diagnosis codes and the recommended dosage of GATTEX for all patients.
PS Weaning and Expectation Setting Guide Shape expectations by learning more about PS weaning.
Real-World Experience Explore real-world patient experiences on GATTEX.
Request a Rep Sign up for emails or schedule a rep visit to learn more about GATTEX.
GATTEX Is an FDA-Approved Glucagon-Like Peptide-2 (GLP-2) Analog1
In clinical studies of adult patients with SBS, GATTEX was proven to:
Significantly reduce weekly PS VOLUME requirements1
Help patients achieve MORE TIME OFF PS1
Help some patients achieve ENTERAL AUTONOMY from PS1
In a 6-month study, 63% (27/43) of adults treated with GATTEX reduced their weekly volume of PS by ≥20% or more vs 30% with placebo (13/43) at Weeks 20 and 24. P=0.002, the primary endpoint. In the same study, adult patients treated with GATTEX achieved a reduction of ≥1 day off PS per week (21/39) vs placebo (9/39), an exploratory endpoint. In the 24-month open-label extension, adult patients previously treated with GATTEX weaned off PS completely after 30 months of treatment (10/30).1
In a 6-month study, pediatric patients treated with GATTEX reduced weekly PS volume by ≥20% (18/26), the primary endpoint. They also achieved a reduction of ≥1 day off PS per week (10/26)—mean PS infusion time at baseline was 7 days/week—and patients weaned off PS completely (3/26), secondary endpoints.1
Start Patients
on GATTEX
Find what you need, including dosing and administration guidance, to help your adult or pediatric patients get started on GATTEX.
Build a PS
Weaning Plan
Learn more about how to best support your patients on GATTEX by helping to reduce PS and, in some, achieve enteral autonomy.
Find Helpful Resources
Download essential forms, brochures, and more resources to support you, your office staff, and your patients on GATTEX.
